Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Teva Pharmaceutical Industries Ltd. has begun launching AHZANTIVE®, an EMA-approved biosimilar to Eylea® (aflibercept), across multiple European countries. This launch broadens Teva's biosimilar portfolio, strengthens its presence in ophthalmology, and supports its Pivot to Growth strategy by improving patient access to biologic medicines for retin…